Alamar Biosciences and DZNE Collaborate on Proteomic Profiling in the Rhineland
Wednesday, July 30, 2025
Alamar Biosciences has announced a partnership with the German Center for Neurodegenerative Diseases (DZNE) to support large-scale proteomic profiling as part of the Rhineland, a major population-based ageing initiative.
The collaboration will utilise Alamar’s ultra-sensitive NULISAseq™ CNS Disease Panel 120 and Inflammation Panel 250 to analyse 23,000 plasma samples from this project, along with additional samples from disease-specific DZNE cohorts.
The Rhineland project, led by DZNE, is one of the world’s most extensive longitudinal research efforts focused on healthy ageing and neurodegenerative conditions. It includes detailed clinical, demographic, imaging, genetic, and lifestyle data from thousands of participants over several decades.
Through this partnership, researchers will use Alamar’s CNS Disease Panel to measure hundreds of brain-related proteins in small blood volumes. The panel offers high specificity, including the ability to differentiate brain-derived phosphorylated tau from total phosphorylated tau—an important factor for early detection and risk assessment in diseases such as Alzheimer’s. The Inflammation Panel will further support the initiative by enabling broad and sensitive profiling of immune-related proteins linked to ageing and neuroinflammation.
The integration of proteomic data with other datasets from the Rhineland is expected to support early biomarker discovery, improve understanding of cognitive decline, and aid in the development of targeted diagnostics and therapies.
By combining advanced proteomic tools with one of the most deeply characterised ageing populations, the initiative aims to enhance early detection, improve clinical outcomes, and contribute to the development of new therapeutic approaches for brain-related disorders.
This collaboration reflects a shared commitment to advancing research into ageing and neurodegenerative diseases.
Source: alamarbio.com
